Prostate cancer
Conditions
Brief summary
The primary endpoint is spatially defined aggressive PC lesions, or subparts of lesions, identified and defined using PSMA-PET and/or mpMRI compared to histopathology
Detailed description
The secondary endpoints are biochemical disease-free survival, time to relapse, overall survivor and surgical margins., The secondary endpoint is to the assess the radiological extracapsular extension and seminal vesicle involvement in comparison to histopathological evaluation., The exploratory endpoint of the study is also the spatially defined most aggressive PC lesions, or subparts of lesions., The safety endpoint is subject-reported adverse events up to one week after treatment.
Interventions
DRUG18F-PSMA-1007
DRUGBuscopan 20 mg/ml injektionsvätska
DRUGlösning
DRUGDotarem 279
DRUG3 mg/ml injektionsvätska lösning
DRUGGlucagon Novo Nordisk 1 mg pulver och vätska till injektionsvätska
Sponsors
Region Vasterbotten, Umea University
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is spatially defined aggressive PC lesions, or subparts of lesions, identified and defined using PSMA-PET and/or mpMRI compared to histopathology | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints are biochemical disease-free survival, time to relapse, overall survivor and surgical margins., The secondary endpoint is to the assess the radiological extracapsular extension and seminal vesicle involvement in comparison to histopathological evaluation., The exploratory endpoint of the study is also the spatially defined most aggressive PC lesions, or subparts of lesions., The safety endpoint is subject-reported adverse events up to one week after treatment. | — |
Countries
Sweden
Outcome results
None listed